Swiss National Bank grew its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 16.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,800 shares of the company's stock after acquiring an additional 3,400 shares during the period. Swiss National Bank owned about 0.09% of GeneDx worth $1,829,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. MCF Advisors LLC raised its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock worth $27,000 after acquiring an additional 182 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of GeneDx during the 4th quarter worth approximately $28,000. Evolution Wealth Advisors LLC purchased a new stake in GeneDx in the 4th quarter valued at approximately $202,000. Victory Capital Management Inc. acquired a new stake in GeneDx during the 4th quarter valued at $209,000. Finally, Point72 DIFC Ltd acquired a new stake in GeneDx during the 3rd quarter valued at $220,000. Hedge funds and other institutional investors own 61.72% of the company's stock.
Insider Buying and Selling at GeneDx
In related news, CEO Katherine Stueland sold 51,420 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the completion of the sale, the chief executive officer now owns 1,720 shares of the company's stock, valued at approximately $162,505.60. This represents a 96.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 1,430 shares of GeneDx stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20. Following the transaction, the chief financial officer now directly owns 26,770 shares in the company, valued at approximately $2,035,590.80. This trade represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 183,032 shares of company stock worth $17,007,198 in the last quarter. 27.30% of the stock is owned by insiders.
GeneDx Trading Up 0.3 %
NASDAQ:WGS traded up $0.28 during mid-day trading on Wednesday, reaching $84.87. The company's stock had a trading volume of 615,336 shares, compared to its average volume of 648,381. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock has a market cap of $2.38 billion, a P/E ratio of -43.30 and a beta of 1.91. The company's fifty day simple moving average is $88.05 and its two-hundred day simple moving average is $75.23. GeneDx Holdings Corp. has a twelve month low of $8.63 and a twelve month high of $115.60.
GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. On average, equities analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms recently commented on WGS. TD Cowen increased their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group raised their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $72.33.
Check Out Our Latest Analysis on GeneDx
GeneDx Profile
(
Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Further Reading
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
